Zimmer Biomet Holdings, Inc. (ZBH)

In the past six months, Zimmer Biomet's stock has been impacted by several events. Q3 2025 financial results revealed distributor order cancellations and a revenue miss in Latin America, leading to a stock decline and a shareholder rights law firm investigation. Q4 and full-year 2025 results showed strong net sales, and a new stock repurchase authorization was announced. An SVP sold shares of ZBH stock. Q1 2026 financial results exceeded analyst estimates, and a CFO transition was announced. Analysts adjusted their ratings and price targets for ZBH. The stock price has fallen and moved below its 50-day moving average, indicating potential downward trends.

Demand for Zimmer Biomet's products is driven by procedure volumes, influenced by aging demographics and elective surgery volumes. The business model is affected by the pace of elective procedures, hospital purchasing patterns, and the adoption of advanced surgical systems. The healthcare equipment sector benefits from recurring demand due to medical necessity. Specific seasonal peaks or troughs in demand are not detailed in the available information.

Zimmer Biomet Holdings, Inc. is a global medical technology company in the Healthcare sector, focusing on Medical Devices & Instruments. It designs, manufactures, and markets orthopedic reconstructive products, sports medicine, biologics, extremities, trauma, spine, craniomaxillofacial, thoracic, surgical, and dental implant products. Key products include knee replacement systems like the Persona Knee and hip replacement systems like the Taperloc Hip System. The company also offers integrated digital and robotic technologies, including the ROSA Robotics platform.

Zimmer Biomet has a global presence, selling products in over 100 countries and operating approximately 25 to 39 manufacturing facilities. In 2024, net sales were distributed as follows: 57.8% from the United States, 22% from Europe/Middle East/Africa (EMEA), 15.5% from Asia/Pacific, and 4.7% from the Americas (excluding the U.S.). The Asia-Pacific region has historically shown strong performance.

Zimmer Biomet's brand reputation has experienced both positive recognition and challenges in the past year. The company was recognized as one of the best companies to work for in Europe by Fortune. However, a shareholder rights law firm initiated an investigation following disclosures that questioned the company's confidence in its 2025 revenue targets, scrutinizing whether management misled investors regarding the stability of its international business.

Zimmer Biomet's shareholder base is predominantly institutional, with 942 institutional owners holding approximately 95.68% to 101.39% of the company. Major institutional owners include Dodge & Cox, The Vanguard Group, and BlackRock, Inc. Individual investors hold about 0.18% of the shares, while insiders own approximately 31.27%. Tpg Group Holdings Sbs Advisors Inc is a large individual shareholder.